The history of vaccination against cytomegalovirus

Plotkin, Stanley

doi:10.1007/s00430-015-0388-z

Cited by 71Cytomegalovirus and herpesvirus researchHerpesvirus Infections and TreatmentsAnimal Virus Infections Studies

The history of vaccination against cytomegalovirus

Plotkin, Stanley·2015·Medical Microbiology and Immunology

DOI 10.1007/s00430-015-0388-z

Open this paper in CoChat — free account

Abstract

Cytomegalovirus vaccine development started in the 1970s with attenuated strains. In the 1980s, one of the strains was shown to be safe and effective in renal transplant patients. Then, attention switched to glycoprotein gB, which was shown to give moderate but transient protection against acquisition of the virus by women. The identification of the pp65 tegument protein as the principal target of cellular immune responses resulted in new approaches, particularly DNA, plasmids to protect hematogenous stem cell recipients. The subsequent discovery of the pentameric protein complex that generates most neutralizing antibodies led to efforts to incorporate that complex into vaccines. At this point, there are many candidate CMV vaccines, including live recombinants, replication-defective virus, DNA plasmids, soluble pentameric proteins, peptides, virus-like particles and vectored envelope proteins.

Integrity signals

Registry

Crossref · 10.1007/s00430-015-0388-z

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

We know the antigens needed in a HCMV vaccine.
“Therefore, we know the antigens needed in a HCMV vaccine, and that vaccination can be protective.”
From Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention (2019) · cites this paper as [222]
HCMV vaccination can be protective.
“Therefore, we know the antigens needed in a HCMV vaccine, and that vaccination can be protective.”
From Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention (2019) · cites this paper as [222]

Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor
Walter, E. A., Greenberg, P. D., Gilbert, M. J., Finch, R. J., Watanabe, K. S., Thomas, E. D., & Riddell, S. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510193331603 · Cited by 1,766 · see citing works
New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection
Dollard, S. C., Grosse, S. D., & Ross, D. S. (2007) · Reviews in Medical Virology · doi:10.1002/rmv.544 · Cited by 1,260 · see citing works
Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome
Stagno, S. (1986) · JAMA · doi:10.1001/jama.256.14.1904 · Cited by 968 · see citing works
Vaccine Prevention of Maternal Cytomegalovirus Infection
Pass, R. F., Zhang, C., Evans, A., Simpson, T. Y., Andrews, W. J., Huang, M.-L. W., Corey, L., Hill, J., Davis, E., Flanigan, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0804749 · Cited by 711 · see citing works
Nonviral delivery of self-amplifying RNA vaccines
Geall, A. J., Verma, A., Otten, G. R., Shaw, C. A., Hekele, A., Banerjee, K., Cu, Y., Beard, C. W., Brito, L. A., Krucker, T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209367109 · Cited by 675 · cited 1× · see citing works
“1 3 Meanwhile, Novartis has adopted the self-replicating RNA strategy, in which RNA for the major candidate antigens is produced in vitro and then injected in vivo, where transcription generates the proteins [63].”
INTRACEREBRAL HÆMORRHAGE
Hayward, R. D., & OʼReilly, G. V. (1976) · The Lancet · doi:10.1016/s0140-6736(76)92904-4 · Cited by 649 · see citing works
Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains
Cha, T. A., Tom, E., Kemble, G. W., Duke, G. M., Mocarski, E. S., & Spaete, R. R. (1996) · Journal of Virology · doi:10.1128/jvi.70.1.78-83.1996 · Cited by 607 · see citing works
Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism
Wang, D., & Shenk, T. E. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509201102 · Cited by 479 · see citing works
Human Cytomegalovirus UL131-128 Genes Are Indispensable for Virus Growth in Endothelial Cells and Virus Transfer to Leukocytes
Hahn, G., Revello, M. G., Patrone, M., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.18.10023-10033.2004 · Cited by 468 · see citing works
Vaccines for the 21st Century: A Tool for Decisionmaking
Stratton, K. R., Durch, J. S., & Lawrence, R. S. (2013) · Cited by 440 · see citing works
Primary immune responses to human CMV: a critical role for IFN-γ–producing CD4+ T cells in protection against CMV disease
Gamadia, L. E., Remmerswaal, E. B. M., Weel, J. F. L., Bemelman, F. J., van Lier, R. A. W., & ten Berge, I. J. M. (2003) · Blood · doi:10.1182/blood-2002-08-2502 · Cited by 423 · see citing works
Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients
Ljungman, P. T., Hakki, M., & Boeckh, M. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.11.011 · Cited by 422 · see citing works
Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial
Griffiths, P., Stanton, A., McCarrell, E., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60136-0 · Cited by 389 · see citing works
Isolation of Human Monoclonal Antibodies That Potently Neutralize Human Cytomegalovirus Infection by Targeting Different Epitopes on the gH/gL/UL128-131A Complex
Macagno, A., Bernasconi, N. L., Zatta, F., Dander, E., Sarasini, A., Revello, M. G., Gerna, G., Sallusto, F., & Lanzavecchia, A. (2009) · Journal of Virology · doi:10.1128/jvi.01809-09 · Cited by 326 · see citing works
Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response
Britt, W. J., Vugler, L. G., Butfiloski, E. J., et al. (1990) · Journal of Virology · doi:10.1128/jvi.64.3.1079-1085.1990 · Cited by 313 · see citing works
DEVELOPMENT OF A VACCINE AGAINST MENTAL RETARDATION CAUSED BY CYTOMEGALOVIRUS INFECTION IN UTERO
Elek, S. D., & Stern, H. (1974) · The Lancet · doi:10.1016/s0140-6736(74)92997-3 · Cited by 291 · see citing works
Immunity Induced By Primary Human Cytomegalovirus Infection Protects Against Secondary Infection Among Women Of Childbearing Age
Adler, S. P., Starr, S. E., Plotkin, S. A., et al. (1995) · The Journal of Infectious Diseases · doi:10.1093/infdis/171.1.26 · Cited by 255 · see citing works
Self-citation
A Subunit Cytomegalovirus Vaccine Based on Recombinant Envelope Glycoprotein B and a New Adjuvant
Pass, R. F., Duliège, A., Boppana, S. B., et al. (1999) · The Journal of Infectious Diseases · doi:10.1086/315022 · Cited by 250 · see citing works
Development of a Candidate HLA A*0201 Restricted Peptide-Based Vaccine Against Human Cytomegalovirus Infection
Diamond, D. J., York, J., Sun, J., Wright, C. L., & Forman, S. J. (1997) · Blood · doi:10.1182/blood.v90.5.1751 · Cited by 246 · see citing works
Cytomegalovirus Infection: A Driving Force in Human T Cell Immunosenescence
KOCH, S., LARBI, A., ÖZCELIK, D., SOLANA, R., GOUTTEFANGEAS, C., ATTIG, S., WIKBY, A., STRINDHALL, J., FRANCESCHI, C., & PAWELEC, G. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1396.043 · Cited by 242 · see citing works
Impact of Cytomegalovirus in Organ Transplant Recipients in the Era of Antiviral Prophylaxis
Limaye, A. P., Bakthavatsalam, R., Kim, H. W., et al. (2006) · Transplantation · doi:10.1097/01.tp.0000226071.12562.1a · Cited by 241 · see citing works
A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial
Kharfan‐Dabaja, M. A., Boeckh, M., Wilck, M. B., Langston, A. A., Chu, A. H., Wloch, M. K., Guterwill, D. F., Smith, L. R., Rolland, A. P., & Kenney, R. T. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70344-9 · Cited by 231 · see citing works
The history of cytomegalovirus and its diseases
Ho, M. (2007) · Medical Microbiology and Immunology · doi:10.1007/s00430-007-0066-x · Cited by 219 · see citing works
Cytomegalovirus infection in critically ill patients: a systematic review
Osawa, R., & Singh, N. (2009) · Critical Care · doi:10.1186/cc7875 · Cited by 218 · see citing works
Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers
Bernstein, D. I., Reap, E. A., Katen, K., Watson, A., Smith, K., Norberg, P., Olmsted, R. A., Hoeper, A., Morris, J., Negri, S., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.09.135 · Cited by 212 · see citing works
Candidate cytomegalovirus strain for human vaccination
Plotkin, S. A., Furukawa, T., Zygraich, N., et al. (1975) · Infection and Immunity · doi:10.1128/iai.12.3.521-527.1975 · Cited by 202 · see citing works
Self-citation
Fetal Human Cytomegalovirus Transmission Correlates with Delayed Maternal Antibodies to gH/gL/pUL128-130-131 Complex during Primary Infection
Lilleri, D., Kabanova, A., Revello, M. G., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059863 · Cited by 186 · see citing works
A review of genetic differences between limited and extensively passaged human cytomegalovirus strains
Prichard, M. N., Penfold, M. E. T., Duke, G. M., et al. (2001) · Reviews in Medical Virology · doi:10.1002/rmv.315 · Cited by 177 · see citing works
Clinical Trials of Immunization with the Towne 125 Strain of Human Cytomegalovirus
Plotkin, S. A., Farquhar, J. W., & Hornberger, E. (1976) · The Journal of Infectious Diseases · doi:10.1093/infdis/134.5.470 · Cited by 177 · see citing works
Self-citation
Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients
Ljungman, P. T., Hakki, M., & Boeckh, M. (2010) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2010.01.008 · Cited by 161 · see citing works
Significance of herpesvirus immediate early gene expression in cellular immunity to cytomegalovirus infection
Reddehase, M. J., & Koszinowski, U. H. (1984) · Nature · doi:10.1038/312369a0 · Cited by 161 · see citing works
MULTICENTER TRIAL OF TOWNE STRAIN ATTENUATED VIRUS VACCINE IN SERONEGATIVE RENAL TRANSPLANT RECIPIENTS
Plotkin, S. A., Higgins, R. M., Kurtz, J. B., et al. (1994) · Transplantation · doi:10.1097/00007890-199412000-00006 · Cited by 147 · see citing works
Self-citation
Cytotoxic T Lymphocyte (CTL) Responses to Human Cytomegalovirus pp65, IE1‐Exon4, gB, pp150, and pp28 in Healthy Individuals: Reevaluation of Prevalence of IE1‐Specific CTLs
Gyulai, Z., Endrész, V., Burián, K., Pincus, S. E., Toldy, J., Cox, W. I., Meri, C., Plotkin, S. A., & Berencsi, K. (2000) · The Journal of Infectious Diseases · doi:10.1086/315445 · Cited by 142 · see citing works
Self-citation
Safety and Immunogenicity of a Bivalent Cytomegalovirus DNA Vaccine in Healthy Adult Subjects
Wloch, M. K., Smith, L. R., Boutsaboualoy, S., Reyes, L., Han, C. S., Kehler, J., Smith, H. D., Selk, L., Nakamura, R., Brown, J. W., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/588385 · Cited by 139 · see citing works
Comparative Virulence and Immunogenicity of the Towne Strain and a Nonattenuated Strain of Cytomegalovirus
Quinnan, G. V., DELERY, M., ROOK, A. H., et al. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-101-4-478 · Cited by 126 · see citing works
Glycoprotein B Vaccine Is Capable of Boosting Both Antibody and CD4 T-Cell Responses to Cytomegalovirus in Chronically Infected Women
Sabbaj, S., Pass, R. F., Pichon, S., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir138 · Cited by 111 · see citing works
A Phase 1 Study of 4 Live, Recombinant Human Cytomegalovirus Towne/Toledo Chimeric Vaccines
Heineman, T. C., Schleiss, M. R., Bernstein, D. I., Spaete, R. R., Yan, L. K., Duke, G. M., Prichard, M. N., Wang, Z., Yan, Q., Sharp, M., et al. (2006) · The Journal of Infectious Diseases · doi:10.1086/503365 · Cited by 109 · see citing works
Effects of Antigen Dose and Immunization Regimens on Antibody Responses to a Cytomegalovirus Glycoprotein B Subunit Vaccine
Frey, S. E., Harrison, C., Pass, R. F., et al. (1999) · The Journal of Infectious Diseases · doi:10.1086/315060 · Cited by 105 · see citing works
Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers
Mitchell, D. K., Holmes, S. J., BURKE, R. L., et al. (2002) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200202000-00009 · Cited by 98 · see citing works
Clinical Evaluation of Safety and Immunogenicity of PADRE-Cytomegalovirus (CMV) and Tetanus-CMV Fusion Peptide Vaccines With or Without PF03512676 Adjuvant
Rosa, C. L., Longmate, J., Lacey, S. F., Kaltcheva, T. I., Sharan, R., Marsano, D., Kwon, P. D., Drake, J., Williams, B., Denison, S., et al. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis107 · Cited by 96 · see citing works
Safety and immunogenicity of the Towne strain cytomegalovirus vaccine
Adler, S. P., Hempfling, S., Starr, S. E., et al. (1998) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199803000-00006 · Cited by 88 · see citing works
Enveloped Virus-Like Particle Expression of Human Cytomegalovirus Glycoprotein B Antigen Induces Antibodies with Potent and Broad Neutralizing Activity
Kirchmeier, M. J., Fluckiger, A.-C., Soare, C., et al. (2013) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00662-13 · Cited by 85 · see citing works
Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease
Fu, T., An, Z., & Wang, D. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.03.057 · Cited by 85 · see citing works
Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice
Wen, Y., Monroe, J. E., Linton, C. E., Archer, J. F., Beard, C. W., Barnett, S. W., Palladino, G., Mason, P. W., Carfı́, A., & Lilja, A. E. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.05.004 · Cited by 80 · see citing works
Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers
Gönczöl, É., Ianacone, J., Ho, W., et al. (1990) · Vaccine · doi:10.1016/0264-410x(90)90135-9 · Cited by 78 · see citing works
Universal neonatal cytomegalovirus screening using saliva – Report of clinical experience
Barkai, G., Roth, D. A., Barzilai, A., et al. (2014) · Journal of Clinical Virology · doi:10.1016/j.jcv.2014.04.024 · Cited by 72 · see citing works
Specific Cellular and Humoral Immunity after Immunization with Live Towne Strain Cytomegalovirus Vaccine
Starr, S. E., Glazer, J., Friedman, H. M., et al. (1981) · The Journal of Infectious Diseases · doi:10.1093/infdis/143.4.585 · Cited by 72 · see citing works
Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus
Fu, T., Wang, D., Freed, D. C., et al. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.10.053 · Cited by 66 · see citing works
Clinical and Laboratory Studies of Live Cytomegalovirus Vaccine Ad-169
Neff, B. J., Weibel, R. E., Buynak, E. B., et al. (1979) · Experimental Biology and Medicine · doi:10.3181/00379727-160-40382 · Cited by 66 · see citing works
Serum antibody response to the gH/gL/pUL128–131 five-protein complex of human cytomegalovirus (HCMV) in primary and reactivated HCMV infections
Genini, E., Percivalle, E., Sarasini, A., et al. (2011) · Journal of Clinical Virology · doi:10.1016/j.jcv.2011.06.018 · Cited by 64 · see citing works
Immunisation trials with live attenuated cytomegalovirus TOWNE 125
Just, M., Buergin-Wolff, A., Emoedi, G., et al. (1975) · Infection · doi:10.1007/bf01641052 · Cited by 61 · see citing works
A recombinant subunit vaccine approach to HCMV vaccine development.
Spaete, R. R. (1991) · PubMed · Cited by 61 · see citing works
Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection
Wang, D., Li, F., Freed, D. C., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.09.056 · Cited by 61 · see citing works
Cytomegalovirus Vaccine Virus (Towne Strain) Does not Induce Latency
Pwrkin, S. A., & Huang, E.-S. (1985) · The Journal of Infectious Diseases · doi:10.1093/infdis/152.2.395 · Cited by 59 · see citing works
Immune responses to isolated human cytomegalovirus envelope proteins
Gönczöl, É., Hudecz, F., Ianacone, J., et al. (1986) · Journal of Virology · doi:10.1128/jvi.58.2.661-664.1986 · Cited by 53 · see citing works
MULTICENTER TRIAL OF TOWNE STRAIN ATTENUATED VIRUS VACCINE IN SERONEGATIVE RENAL TRANSPLANT RECIPIENTS
Plotkin, S. A., Higgins, R. M., Kurtz, J. B., et al. (1994) · Transplantation · doi:10.1097/00007890-199412270-00006 · Cited by 51 · see citing works
Self-citation
Cytomegalovirus Vaccine Strain Towne-Derived Dense Bodies Induce Broad Cellular Immune Responses and Neutralizing Antibodies That Prevent Infection of Fibroblasts and Epithelial Cells
Cayatte, C., Schneider-Ohrum, K., Wang, Z., Irrinki, A., Nguyen, N., Lu, J., Nelson, C. L., Servat, E., Gemmell, L., Citkowicz, A., et al. (2013) · Journal of Virology · doi:10.1128/jvi.01554-13 · Cited by 49 · see citing works
Vaccination of Pediatric Nurses With Live Attenuated Cytomegalovirus
FLEISHER, G. R. (1982) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.1982.03970400012003 · Cited by 47 · see citing works
Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies
Loomis, R. J., Lilja, A. E., Monroe, J. E., Balabanis, K. A., Brito, L. A., Palladino, G., Franti, M., Mandl, C. W., Barnett, S. W., & Mason, P. W. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.12.009 · Cited by 43 · see citing works
Cytomegalovirus pp65 limits dissemination but is dispensable for persistence
Malouli, D., Hansen, S. G., Nakayasu, E. S., Marshall, E. E., Hughes, C. M., Ventura, A. B., Gilbride, R. M., Lewis, M. S., Xu, G., Kreklywich, C. N., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67420 · Cited by 38 · see citing works
Clinical Development of a Cytomegalovirus DNA Vaccine: From Product Concept to Pivotal Phase 3 Trial
Smith, L. R., Wloch, M. K., Chaplin, J., Gerber, M., & Rolland, A. P. (2013) · Vaccines · doi:10.3390/vaccines1040398 · Cited by 38 · see citing works
Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients
Jacobson, M. Z., Sinclair, E., Bredt, B. M., Agrillo, L., Black, D., Epling, C. L., Carvidi, A. B., Ho, T. N., Bains, R., & Adler, S. P. (2006) · Journal of Clinical Virology · doi:10.1016/j.jcv.2005.09.019 · Cited by 35 · see citing works
Modeling the potential impact of vaccination on the epidemiology of congenital cytomegalovirus infection
Lanzieri, T. M., Bialek, S. R., Ortega‐Sanchez, I. R., & Gambhir, M. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.05.014 · Cited by 35 · see citing works
The next generation recombinant human cytomegalovirus vaccine candidates—Beyond gB
Lilja, A. E., & Mason, P. W. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.09.056 · Cited by 33 · see citing works
T-Lymphocyte Subsets and Proliferative Responses Following Immunization with Cytomegalovirus Vaccine
Carney, W. P., Hirsch, M. S., Iacoviello, V. R., et al. (1983) · The Journal of Infectious Diseases · doi:10.1093/infdis/147.5.958 · Cited by 29 · see citing works
COMMITTEE TO STUDY PRIORITIES FOR VACCINE DEVELOPMENT
Stratton, K. R., Durch, J. S., & Lawrence, R. S. (2000) · Cited by 25 · see citing works
Resistance of Seropositive Volunteers to Subcutaneous Challenge with Low-Passage Human Cytomegalovirus
Plofkin, S. A., Weibel, R. E., Alpert, G., et al. (1985) · The Journal of Infectious Diseases · doi:10.1093/infdis/151.4.737 · Cited by 24 · see citing works
Detection of Antibody to Cytomegalovirus Early Antigen in Vaccinated, Normal Volunteers and Renal Transplant Candidates
Friedman, A. D., Furukawa, T., & Plotkin, S. A. (1982) · The Journal of Infectious Diseases · doi:10.1093/infdis/146.2.255 · Cited by 24 · see citing works
Self-citation
Optimized recombinant dense bodies of human cytomegalovirus efficiently prime virus specific lymphocytes and neutralizing antibodies without the addition of adjuvant
Becke, S., Aue, S., Thomas, D., Schader, S. I., Podlech, J., Bopp, T., Sedmak, T., Uwe Wolfrum, B., Plachter, B., & Reyda, S. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.07.016 · Cited by 23 · see citing works
Vaccination with synthetic constructs expressing cytomegalovirus immunogens is highly T cell immunogenic in mice
Shedlock, D. J., Talbott, K. T., Wu, S. J., Wilson, C., Muthumani, K., Boyer, J., Sardesai, N. Y., Awasthi, S., & Weiner, D. B. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.22447 · Cited by 22 · see citing works
Detection of antibodies to pre-early nuclear antigen and immediate-early antigens in patients immunized with cytomegalovirus vaccine
Friedman, A. D., Michelson, S., & Plotkin, S. A. (1982) · Infection and Immunity · doi:10.1128/iai.38.3.1068-1072.1982 · Cited by 12 · see citing works
Self-citation
Cytomegalovirus vaccine prepared in WI-38.
Sa, P., & Huygelen, C. (1978) · PubMed · Cited by 12 · see citing works

Flagged first, then by citations

Sorted by citations

Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention
Aiello, A., Farzaneh, F., Candore, G., Caruso, C., Davinelli, S., Gambino, C. M., Ligotti, M. E., Zareian, N., & Accardi, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02247 · Cited by 693 · see citing works

Enveloped Virus Is the Major Virus Form Produced during Productive Infection with the Modified Vaccinia Virus Ankara Strain
Spehner, D., Drillien, R., Proamer, F., et al. (2000) · Virology · doi:10.1006/viro.2000.0411 · Cited by 21 · see citing works
Inactivation of West Nile virus, vaccinia virus and viral surrogates for relevant and emergent viral pathogens in plasma‐derived products
Remington, K. M., Trejo, S. J., Buczynski, G., et al. (2004) · Vox Sanguinis · doi:10.1111/j.1423-0410.2004.00530.x · Cited by 53 · see citing works
Proliferative and cytotoxic T cells to AIDS virus glycoproteins in chimpanzees immunized with a recombinant vaccinia virus expressing AIDS virus envelope glycoproteins.
Zarling, J. M., Eichberg, J. W., Moran, P. A., et al. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.4.988 · Cited by 98 · see citing works
Protection against lethal Japanese encephalitis virus infection of mice by immunization with the highly attenuated MVA strain of vaccinia virus expressing JEV prM and E genes
Nam, J., Wyatt, L. S., Chae, S.-L., et al. (1999) · Vaccine · doi:10.1016/s0264-410x(98)00156-x · Cited by 42 · see citing works
Immunogenicity of Recombinant Vaccinia Viruses that Display the HIV Type 1 Envelope Glycoprotein on the Surface of Infectious Virions
Katz, E., & Moss, B. A. (1997) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1997.13.1497 · Cited by 18 · see citing works

Authors: Plotkin, S.
Affiliations: University of Pennsylvania (US)
Corresponding author: Plotkin, Stanley
ORCID: Plotkin, Stanley
Venue: Medical Microbiology and Immunology
Publisher: Springer Science and Business Media LLC
Published: 2015-03-20
Volume: 204
Issue: 3
Pages: 247-254
ISSN: 0044-3077 (ISSN-L)
0300-8584
1432-1831
DOI: 10.1007/s00430-015-0388-z
OpenAlex: W2155955448
Cited by: 71
References: 72
Citations by year: 2026: 2 · 2025: 3 · 2024: 4 · 2023: 4 · 2022: 2 · 2021: 9 · 2020: 5 · 2019: 4 · 2018: 8 · 2017: 13 · 2016: 13 · 2015: 4
FWCI: 1.65
Type: journal article
Language: en
Open access: closed
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Medical Microbiology and Immunology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Epidemiology › Cytomegalovirus and herpesvirus research
Health Sciences › Medicine › Epidemiology › Herpesvirus Infections and Treatments
Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Keywords: cytomegalovirus vaccine, vaccine development history, kidney transplant recipients, cell-mediated immunity, DNA plasmid vaccine, hematopoietic stem cell transplantation, neutralizing antibodies, replication-defective virus, virus-like particles, envelope protein, vaccine candidate
MeSH terms: Antibodies, Viral, Cytomegalovirus Infections, Cytomegalovirus, Humans, Vaccination, Cytomegalovirus Vaccines, History, 20th Century, History, 21st Century, Antibodies, Neutralizing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The history of vaccination against cytomegalovirus

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks